Redeye provides a research update on Faron following the company’s recent H1 report.
Redeye comments on Faron's updated BEXMAB data presented at EHA 2026, which demonstrated continued maturation of the clinical and translatio...
Redeye comments on Faron announcing an agreement with Parexel to support the randomized phase IIb BEXERA trial of bexmarilimab in treatment-...
Redeye comments on Faron’s announcement of the final outcome of its EUR40m rights issue, which delivered gross proceeds of approximately EUR...
Redeye comments on Faron’s announcement of the final terms of its previously communicated rights issue.
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent annual report.
Redeye comments on Faron’s announcement of a planned fully pre-emptive rights issue of approximately EUR40m, aimed at funding the next phase...
Redeye comments on Faron’s announcements of the phase I/II investigator-initiated trials BEXAR and BLAZE, evaluating bexmarilimab in metasta...
Redeye comments on Faron’s decision to trigger the second €10m tranche of the Heights Capital Management convertible bond.
Redeye comments on Faron’s updated BEXMAB data presented at the ESMO 2025 congress, which further strengthens the clinical and mechanistic f...
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H1 report.
Redeye comments on Faron’s announcement that it has reached alignment with the FDA on the registrational pathway for bexmarilimab in frontli...
Redeye comments on Faron’s updated data from the Phase I/II BEXMAB trial in frontline high-risk MDS, showing a notable increase in complete ...
Redeye comments on Faron’s ASCO 2025 presentation of full phase II BEXMAB data in high-risk MDS.
Redeye comments on Faron’s recent publication in a scientific journal, which provides valuable mechanistic insights into bexmarilimab’s acti...
Redeye comments on Faron’s announcement that the phase II BEXMAB trial has met its primary endpoint in treatment-resistant high-risk MDS.
Redeye provides a research note on Faron Pharmaceuticals following the announcement of a convertible bond agreement of up to EUR35m.
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H2 report.
Redeye provides a research note on Faron Pharmaceuticals following the outcome of the company’s recent share issue.
Redeye leaves a comment following the promising recent interim data from Faron’s BEXMAB study and interactions with regulatory authorities.
Redeye leaves a comment on Faron’s recent pipeline update, suggesting that the company may look to expand its targeted indications to autoin...
Redeye leaves a note following Faron’s announcement of positive feedback from its meeting with the FDA ahead of phase III trials.
Redeye provides a research update on Faron Pharmaceuticals following the outcome of the company’s recent share issue and clinical progress w...
Redeye leaves a comment following Faron’s announcement of a share issue raising up to EUR30.
Redeye leaves a comment following the first results published from the phase II part of the company’s ongoing BEXMAB study.
Redeye leaves a comment following Faron’s announcement of a change in its CEO position.
Redeye leaves a comment following Faron’s announcement of a conducted private placement raising EUR4.
Redeye leaves a comment following the recently announced updated data from the BEXMAB study with the company’s lead candidate bexmarilimab.
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent annual report, precarious financial situation, and...
Redeye leaves a comment following Faron’s announcement of binding commitments for convertible loans of a total amount of EUR3.
Redeye leaves a comment following the recent announcement by Faron stating that the company is in several Events of Default following possib...
Redeye leaves a comment following the recently announced updated data from the BEXMAB and MATINS studies with the company’s lead candidate b...
Redeye provides a comment following Faron’s announcement of the initiation of the phase II part of the ongoing BEXMAB study.
Redeye provides a short update following Faron’s recent clinical data update from the phase I/II BEXMAB study with its lead candidate, bexma...
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent half-year report and clinical progress with lead c...
Redeye leaves a note following Faron’s recent study update from the phase I/II BEXMAB study with its lead candidate, bexmarilimab.
Redeye leaves a note following Faron’s additional study update from the phase I/II BEXMAB study with lead candidate Bexmarilimab.
Redeye is encouraged to learn that Faron has received positive FDA feedback and recommendations for the future development of lead candidate...
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H2 report and clinical progress with lead candidat...
Redeye leaves a comment on Faron Pharmaceutical's recent private placement.
Redeye leaves a note following an announced trial update from the phase I/II BEXMAB study with lead candidate Bexmarilimab.
Faron has announced an interim trial update from the phase I/II BEXMAB study with lead candidate Bexmarilimab.
Redeye leaves a comment on Faron Pharmaceutical's recent capital raise.
Faron has announced top-line data on dose variation from the phase I/II MATINS study with lead candidate Bexmarilimab.
Redeye leaves a comment on the H1 report published by Faron Pharmaceuticals earlier today.
Redeye leaves a comment following Faron Pharmaceutical’s announcement earlier today of a placing of newly issued treasury shares.
Faron announced earlier today that the company’s New Drug (IND) application to initiate the phase I/II BEXMAB study with lead candidate Bexm...
Redeye initiates coverage of Faron Pharmaceuticals, a Finnish biotech company focused on developing next-generation immunotherapy, its three...
